Developer docs
API playgroundTry for free, no card

Search company profiles

Newronika

Full company profile

uuid0000rnz

Namestring
Newronika
Legal namestring
Newronika S.p.A.
Websiteurl
newronika.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Newronika S.p.A. is an Italian neurotechnology company founded in 2011 as a spin-off from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, built on over 20 years of academic research into adaptive deep brain stimulation. The company develops the αDBS (AlphaDBS) platform, a CE-marked adaptive closed-loop deep brain stimulation system for Parkinson's disease that continuously senses patient brain signals minute-by-minute and automatically adjusts stimulation parameters in real time. Core technical components include a patented proportional control algorithm that linearly tracks neural biomarkers, full-spectrum α/β brain signal sensing captured every 10 minutes with asymmetric sensing during stimulation, the WebBioBank cloud-based neural data platform that aggregates longitudinal implant data for AI-powered therapy optimization and biomarker discovery, and a remote patient monitoring module that enables at-home data collection and reduces in-clinic visit burden.

The company sells implantable adaptive DBS hardware systems directly to hospitals, academic medical centers, and specialized movement disorder clinics in the European Economic Area, supported by field-based Clinical Field Engineers and Clinical Scientists who provide procedural support, programming training, and ongoing clinical partnership. A US subsidiary (Newronika USA Inc., Goose Creek, South Carolina) supports an FDA Investigational Device Exemption-approved clinical trial as a precursor to U.S. commercial launch. Clinical validation comes from a double-blind randomized crossover study (N=19, Parkinson's Disease) showing 86% patient preference for αDBS over conventional DBS, +23% additional waking hours with good symptom relief, and 2.4× longer continuous symptom relief versus a leading competitor; 100% of replacement patients with prior conventional DBS preferred aDBS.

Newronika has raised approximately €30.2 million in cumulative funding across a 2016 venture round (€1.7M), a 2019 Series A (€8.4M), EIC Accelerator grant and blended finance (€4.5M total, 2022-2024), and a 2025 Series B (€13.6M / $14.1M) from investors including Innogest Capital, Indaco Venture Partners, F3F, Omnes Capital, ENEA Tech e Biomedical, TNBT Capital, Wille Finance, Atlante Ventures, and the Michael J. Fox Foundation. The company's leadership combines co-founder technical leadership (Lorenzo Rossi, CEO & CTO; Alberto Priori, SAB Chairman) with recently appointed strategic oversight (Keith Carlton, Executive Chairman, September 2025).

Short descriptiontext

Newronika is an Italian neurotechnology company developing the αDBS adaptive deep brain stimulation platform, which continuously monitors brain signals and automatically adjusts stimulation for Parkinson's disease patients. The CE-marked system is sold to hospitals and movement disorder clinics across the European Economic Area.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCologno Monzese, Italy
HQ citystring
Cologno Monzese
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
adaptive deep brain stimulation, neuromodulation devices, Parkinson's disease therapy, implantable neurostimulators, brain-computer interfaces
Industry1 code
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Neuromodulation Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Adaptive DBS Hardware and Implant Systems
TypeHardware Sales
Description

Sale of implantable adaptive deep brain stimulation devices and associated hardware components. The αDBS system is CE marked and commercially available in the European Economic Area, generating revenue through device sales to hospitals and clinics.

newronika.com
2Clinical Support and Professional Services
TypeProfessional Services
Description

Field-based clinical engineering and scientific support services provided to healthcare institutions implementing the aDBS platform, including training, programming support, and ongoing therapy optimization.

newronika.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Adaptive DBS System (αDBS)
ModelOtherBilling cadenceMulti-year contract
Notes

Device is commercially available in the European Economic Area following CE Mark approval. Specific pricing not publicly disclosed; sales conducted through direct institutional procurement.

newronika.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1αDBS (AlphaDBS)
Description

Adaptive deep brain stimulation platform that monitors brain signals in real-time and automatically adjusts stimulation parameters for patients with movement disorders including Parkinson's disease

newronika.com
+1 more record
Core offering1 text field

Newronika develops and sells the αDBS (AlphaDBS) adaptive deep brain stimulation platform, an implantable neurostimulation system for Parkinson's disease patients. The platform combines closed-loop implantable hardware, a patented proportional control algorithm, full-spectrum brain sensing, and the WebBioBank cloud-based AI data platform, with remote patient monitoring capabilities. The system is CE-marked and commercially available in the European Economic Area, sold to hospitals and specialized movement disorder centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 86% patient preference for αDBS over conventional DBS in double-blind randomized crossover study (N=19)
+3 more records
Product overview1 text field

Newronika offers a single unified adaptive deep brain stimulation platform called αDBS, which includes multiple integrated components: the adaptive closed-loop stimulation system (core therapy delivery), the patented proportional control algorithm (real-time biomarker tracking), Full-Spectrum Brain Sensing (α/β spectrum capture every 10 minutes), the WebBioBank cloud-based neural data platform (AI-powered data storage and biomarker discovery), and Remote Patient Monitoring (automatic at-home data collection). The system is CE-marked and commercially available in Europe for Parkinson's disease patients, with FDA IDE approval for U.S. clinical trials.

Product and service2 records
1αDBS (AlphaDBS) Adaptive Deep Brain Stimulation Platform
CategoryImplantable Neuromodulation Device
Description

Implantable adaptive deep brain stimulation system for Parkinson's disease that continuously monitors brain signals minute-by-minute and automatically adjusts stimulation in real time, responding to each patient's unique neural biomarkers through a patented proportional control algorithm. CE-marked and sold to hospitals and specialized movement disorder clinics.

2WebBioBank Cloud-Based Neural Data Platform
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of Italy's leading research institutions and founding research partner of Newronika spin-off. Source of two decades of foundational R&D for adaptive DBS technology.

newronika.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading Italian university and founding research partner of Newronika spin-off. Co-founders include faculty from University of Milan conducting neuromodulation research.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The global leader in deep brain stimulation with the Activa and Percept PC (with BrainSense adaptive sensing) platforms. Direct competitor in the DBS market targeting Parkinson's disease and other movement disorders, with substantially greater commercial scale and an early adaptive-sensing feature in Percept PC.

TypeDirect peer
Description

Develops the Evoke closed-loop spinal cord stimulation system using neural-response feedback — the closest direct analog to Newronika's closed-loop adaptive technology in the neuromodulation space. Comparable business model and underlying sensing-and-adapt paradigm, applied to a different target indication.

TypeDirect peer
Description

Markets the Vercise and Vercise Genus DBS systems, with directional leads and Bluetooth-based programming. Direct competitor in the Parkinson's DBS market with established commercial presence and ongoing platform development.

TypeEmerging player
Description

Developer of the RNS System, a closed-loop responsive neurostimulation device for epilepsy. Applies the same sensing-and-adapt paradigm as αDBS but targets a different indication (epilepsy vs. Parkinson's). Publicly traded (NPCE), providing a valuation benchmark for closed-loop neurostimulation.

TypeEmerging player
Description

Focused on DBS for cognitive and memory disorders including Alzheimer's disease. Applies DBS technology to neurological indications beyond Parkinson's, partially overlapping with Newronika's potential indication expansion roadmap.

TypeEmerging player
Description

Swiss developer of directional DBS leads and full DBS systems (directSTIM, direcTONIC). Comparable in size and stage to Newronika, with overlap in DBS innovation focus though without the same closed-loop sensing emphasis.

7PINS Medical
TypeDirect peer
Description

Chinese DBS device manufacturer with a portfolio of implantable pulse generators and electrode leads for Parkinson's disease and other movement disorders. Direct DBS competitor, primarily serving China and select Asia-Pacific markets.

8SceneRay
TypeDirect peer
Description

China-based developer of DBS systems for Parkinson's disease, epilepsy, and other neurological indications. Direct competitor in the DBS market, primarily serving the Chinese market with growing international presence.

TypeOthers
Description

Provider of neural interface technology, electrodes, and research tools used in DBS and brain-computer interface research. Adjacent/enabling player supplying components and technology that underpin DBS and neuromodulation R&D, including work with academic partners that overlap with Newronika's institutional research base.

10Abbott
TypeDirect peer
Description

Markets the Infinity DBS system following its St. Jude Medical acquisition. Direct competitor in the DBS space with established hospital sales channels and a broad neuromodulation portfolio spanning DBS and spinal cord stimulation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Newronika

Neuromodulation Medical Devicesnewronika.com

Newronika is an Italian neurotechnology company developing the αDBS adaptive deep brain stimulation platform, which continuously monitors brain signals and automatically adjusts stimulation for Parkinson's disease patients. The CE-marked system is sold to hospitals and movement disorder clinics across the European Economic Area.

What Newronika does

Newronika S.p.A. is an Italian neurotechnology company founded in 2011 as a spin-off from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, built on over 20 years of academic research into adaptive deep brain stimulation. The company develops the αDBS (AlphaDBS) platform, a CE-marked adaptive closed-loop deep brain stimulation system for Parkinson's disease that continuously senses patient brain signals minute-by-minute and automatically adjusts stimulation parameters in real time. Core technical components include a patented proportional control algorithm that linearly tracks neural biomarkers, full-spectrum α/β brain signal sensing captured every 10 minutes with asymmetric sensing during stimulation, the WebBioBank cloud-based neural data platform that aggregates longitudinal implant data for AI-powered therapy optimization and biomarker discovery, and a remote patient monitoring module that enables at-home data collection and reduces in-clinic visit burden.

The company sells implantable adaptive DBS hardware systems directly to hospitals, academic medical centers, and specialized movement disorder clinics in the European Economic Area, supported by field-based Clinical Field Engineers and Clinical Scientists who provide procedural support, programming training, and ongoing clinical partnership. A US subsidiary (Newronika USA Inc., Goose Creek, South Carolina) supports an FDA Investigational Device Exemption-approved clinical trial as a precursor to U.S. commercial launch. Clinical validation comes from a double-blind randomized crossover study (N=19, Parkinson's Disease) showing 86% patient preference for αDBS over conventional DBS, +23% additional waking hours with good symptom relief, and 2.4× longer continuous symptom relief versus a leading competitor; 100% of replacement patients with prior conventional DBS preferred aDBS.

Newronika has raised approximately €30.2 million in cumulative funding across a 2016 venture round (€1.7M), a 2019 Series A (€8.4M), EIC Accelerator grant and blended finance (€4.5M total, 2022-2024), and a 2025 Series B (€13.6M / $14.1M) from investors including Innogest Capital, Indaco Venture Partners, F3F, Omnes Capital, ENEA Tech e Biomedical, TNBT Capital, Wille Finance, Atlante Ventures, and the Michael J. Fox Foundation. The company's leadership combines co-founder technical leadership (Lorenzo Rossi, CEO & CTO; Alberto Priori, SAB Chairman) with recently appointed strategic oversight (Keith Carlton, Executive Chairman, September 2025).

Newronika firmographics

Firmographics
Name
Newronika
Legal name
Newronika S.p.A.
Website
https://newronika.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Newronika is an Italian neurotechnology company developing the αDBS adaptive deep brain stimulation platform, which continuously monitors brain signals and automatically adjusts stimulation for Parkinson's disease patients. The CE-marked system is sold to hospitals and movement disorder clinics across the European Economic Area.
Ownership category
akta.pro rank

Newronika industry classification

Industry
Product category
Neuromodulation Medical Devices
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Adaptive deep brain stimulation
  • Neuromodulation devices
  • Parkinson's disease therapy
  • Implantable neurostimulators
  • Brain-computer interfaces

Where Newronika is headquartered

Location

Headquarters

HQ city
Cologno Monzese
HQ country
Italy
HQ region
Europe

Offices3 records

Markets served

Newronika business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Adaptive DBS Hardware and Implant Systems: Sale of implantable adaptive deep brain stimulation devices and associated hardware components. The αDBS system is CE marked and commercially available in the European Economic Area, generating revenue through device sales to hospitals and clinics.
  2. Clinical Support and Professional Services: Field-based clinical engineering and scientific support services provided to healthcare institutions implementing the aDBS platform, including training, programming support, and ongoing therapy optimization.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractAdaptive DBS System (αDBS)

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Newronika product offering

Product offering

Core offering

Newronika develops and sells the αDBS (AlphaDBS) adaptive deep brain stimulation platform, an implantable neurostimulation system for Parkinson's disease patients. The platform combines closed-loop implantable hardware, a patented proportional control algorithm, full-spectrum brain sensing, and the WebBioBank cloud-based AI data platform, with remote patient monitoring capabilities. The system is CE-marked and commercially available in the European Economic Area, sold to hospitals and specialized movement disorder centers.

Product overview

Newronika offers a single unified adaptive deep brain stimulation platform called αDBS, which includes multiple integrated components: the adaptive closed-loop stimulation system (core therapy delivery), the patented proportional control algorithm (real-time biomarker tracking), Full-Spectrum Brain Sensing (α/β spectrum capture every 10 minutes), the WebBioBank cloud-based neural data platform (AI-powered data storage and biomarker discovery), and Remote Patient Monitoring (automatic at-home data collection). The system is CE-marked and commercially available in Europe for Parkinson's disease patients, with FDA IDE approval for U.S. clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • αDBS (AlphaDBS): Adaptive deep brain stimulation platform that monitors brain signals in real-time and automatically adjusts stimulation parameters for patients with movement disorders including Parkinson's disease
  • WebBioBank™

Products and services

  • αDBS (AlphaDBS) Adaptive Deep Brain Stimulation Platform Implantable adaptive deep brain stimulation system for Parkinson's disease that continuously monitors brain signals minute-by-minute and automatically adjusts stimulation in real time, responding to each patient's unique neural biomarkers through a patented proportional control algorithm. CE-marked and sold to hospitals and specialized movement disorder clinics.
  • WebBioBank Cloud-Based Neural Data Platform

Quantifiable outcome

  • 86% patient preference for αDBS over conventional DBS in double-blind randomized crossover study (N=19)
  • +3 more outcomes

Companies that use Newronika

Customer profile

Segments3 records

Ideal customer profiles2 records

Newronika technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Newronika partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicocoreStrategic or Co-development PartnerOne of Italy's leading research institutions and founding research partner of Newronika spin-off. Source of two decades of foundational R&D for adaptive DBS technology.
  • University of MilancoreStrategic or Co-development PartnerLeading Italian university and founding research partner of Newronika spin-off. Co-founders include faculty from University of Milan conducting neuromodulation research.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Newronika competitors and assessment

Company assessment

Direct peers

  • Medtronic: The global leader in deep brain stimulation with the Activa and Percept PC (with BrainSense adaptive sensing) platforms. Direct competitor in the DBS market targeting Parkinson's disease and other movement disorders, with substantially greater commercial scale and an early adaptive-sensing feature in Percept PC.
  • Saluda Medical: Develops the Evoke closed-loop spinal cord stimulation system using neural-response feedback — the closest direct analog to Newronika's closed-loop adaptive technology in the neuromodulation space. Comparable business model and underlying sensing-and-adapt paradigm, applied to a different target indication.
  • Boston Scientific: Markets the Vercise and Vercise Genus DBS systems, with directional leads and Bluetooth-based programming. Direct competitor in the Parkinson's DBS market with established commercial presence and ongoing platform development.
  • PINS Medical: Chinese DBS device manufacturer with a portfolio of implantable pulse generators and electrode leads for Parkinson's disease and other movement disorders. Direct DBS competitor, primarily serving China and select Asia-Pacific markets.
  • SceneRay: China-based developer of DBS systems for Parkinson's disease, epilepsy, and other neurological indications. Direct competitor in the DBS market, primarily serving the Chinese market with growing international presence.
  • Abbott: Markets the Infinity DBS system following its St. Jude Medical acquisition. Direct competitor in the DBS space with established hospital sales channels and a broad neuromodulation portfolio spanning DBS and spinal cord stimulation.

Emerging players

  • NeuroPace: Developer of the RNS System, a closed-loop responsive neurostimulation device for epilepsy. Applies the same sensing-and-adapt paradigm as αDBS but targets a different indication (epilepsy vs. Parkinson's). Publicly traded (NPCE), providing a valuation benchmark for closed-loop neurostimulation.
  • Functional Neuromodulation: Focused on DBS for cognitive and memory disorders including Alzheimer's disease. Applies DBS technology to neurological indications beyond Parkinson's, partially overlapping with Newronika's potential indication expansion roadmap.
  • Aleva Neurotherapeutics: Swiss developer of directional DBS leads and full DBS systems (directSTIM, direcTONIC). Comparable in size and stage to Newronika, with overlap in DBS innovation focus though without the same closed-loop sensing emphasis.

Others

  • Blackrock Microsystems: Provider of neural interface technology, electrodes, and research tools used in DBS and brain-computer interface research. Adjacent/enabling player supplying components and technology that underpin DBS and neuromodulation R&D, including work with academic partners that overlap with Newronika's institutional research base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Newronika social profiles

Digital presence

Newronika compliance and trust

Trust signal

Compliance2 records

Newronika financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Newronika leadership team

Management profile

Number of profiles

Profiles10 records

Newronika subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Newronika funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Newronika M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Newronika

What does Newronika do?

Newronika develops and sells the αDBS (AlphaDBS) adaptive deep brain stimulation platform, an implantable neurostimulation system for Parkinson's disease patients. The platform combines closed-loop implantable hardware, a patented proportional control algorithm, full-spectrum brain sensing, and the WebBioBank cloud-based AI data platform, with remote patient monitoring capabilities. The system is CE-marked and commercially available in the European Economic Area, sold to hospitals and specialized movement disorder centers.

Is Newronika a public or private company?

Newronika is a private company. It is classified as venture growth investor backed and is currently operating.

When was Newronika founded?

Newronika was founded in 2011. It employs 11 to 50 people.

Where is Newronika based?

Newronika is headquartered in Cologno Monzese, Italy, in the Europe region.

How does Newronika make money?

Two revenue lines are on record. Adaptive DBS Hardware and Implant Systems are the primary driver. The others are clinical Support and Professional Services.

Who are Newronika's main competitors?

Direct peers on record are Medtronic, Saluda Medical, Boston Scientific, PINS Medical, SceneRay and Abbott. Emerging players are NeuroPace, Functional Neuromodulation and Aleva Neurotherapeutics. Blackrock Microsystems is listed as an others.

Does Newronika have an API?

No public API is recorded for Newronika.

What industry is Newronika in?

Newronika's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 54151 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceNewronika Announces First Participant Implanted in ADVENT Pivotal StudyNewronika announced the first participant in its ADVENT pivotal study received an αDBS implant on September 21 at an Italian hospital. The study compares adaptive and conventional deep brain stimulation for Parkinson's disease and is expected to enroll 104 adults. Enrollment is underway in Italy and soon in the U.S.Medical Device NetworkNewronika’s aDBS system secures CE mark with cloud data integrationNewronika received the CE mark for its αDBS adaptive deep brain stimulation system, which integrates with its WebBioBank cloud platform. The device continuously senses neural activity and adjusts stimulation, building on over 20 years of research. The system remains investigational in the US, with an FDA investigational device exemption for the ADVENT trial.Medical Device NetworkNewronika’s aDBS system secures CE mark with cloud data integrationItalian medtech company Newronika has received CE mark approval for its adaptive deep brain stimulation system αDBS, making it the first regulatory clearance in Europe for an aDBS device that continuously senses neural activity and automatically adjusts stimulation based on patient-specific settings. The system integrates with Newronika's cloud-based platform WebBioBank, which collects neural data from participating centers and supports therapy adjustments over time. The company is also conducting the ADVENT pivotal trial under FDA investigational device exemption to support potential US approval of both conventional and adaptive DBS systems for Parkinson's disease.MassDeviceNewronika picks up CE mark for adaptive deep brain stimMilan-based medical device company Newronika has secured CE mark approval for its adaptive deep brain stimulation (aDBS) system for treating Parkinson's disease. The system is the first aDBS platform to receive European regulatory clearance that continuously senses local field potentials and automatically adjusts stimulation based on patient-specific settings, fully integrated with the company's cloud-based WebBioBank neural data platform. The company is simultaneously pursuing U.S. market entry, having received FDA investigational device exemption approval last year.AijournNewronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of CareNewronika S.p.A., a Milan-based medtech company, has received CE Mark certification for αDBS®, its adaptive deep brain stimulation system, making it the first approved adaptive DBS device that continuously senses neural activity and automatically adjusts stimulation while transmitting data to an integrated cloud platform. The system, built on over 20 years of research, is designed to deliver better outcomes for Parkinson's disease patients with fewer side effects and reduced clinical burden. Newronika is also conducting the ADVENT pivotal trial in the United States and European Union to support FDA approval.PR NewswireNewronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of CareNewronika S.p.A., a Milan-based medtech company, has received CE Mark certification for αDBS®, its adaptive deep brain stimulation system with full WebBioBank™ neural data platform integration, enabling commercial use across the European Economic Area. This marks the first regulatory approval for an adaptive DBS system that continuously senses neural activity and automatically adjusts stimulation based on patient-specific settings, representing a significant advancement over conventional fixed-output DBS therapy. The company is also conducting the ADVENT pivotal trial in the United States and European Union to support FDA approval.PR NewswireNewronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of CareNewronika S.p.A. has received CE Mark certification for αDBS®, its adaptive deep brain stimulation system, enabling commercial use across the European Economic Area. The system is the first adaptive DBS technology approved that continuously senses neural activity via local field potentials and automatically adjusts stimulation in real time, fully integrated with Newronika's WebBioBank™ cloud-based neural data platform. The company also holds FDA Investigational Device Exemption for the ADVENT pivotal trial spanning the United States and European Union, which is designed to support U.S. regulatory approval for both conventional and adaptive DBS in Parkinson's disease treatment.AdvfnNewronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of CareNewronika S.p.A., a Milan-based medtech company, has received CE Mark certification for its αDBS® adaptive deep brain stimulation system, enabling commercial use across the European Economic Area. The system is the first adaptive DBS technology that continuously senses neural activity and automatically adjusts stimulation based on patient-specific settings, fully integrated with Newronika's WebBioBank™ cloud-based neural data platform. The company is also conducting the ADVENT pivotal trial in the United States and European Union to support FDA approval for Parkinson's disease treatment.Mpo-magNewronika Wins EU Nod for Adaptive Deep Brain StimNewronika received CE mark certification for its αDBS adaptive deep brain stimulation system, integrated with WebBioBank. The system continuously senses neural activity and adjusts stimulation, marking the first approval for such adaptive DBS. The company also has an FDA IDE for its ADVENT trial to support approval of both conventional and adaptive DBS for Parkinson's disease.BioWorldNewronika gains CE mark for adaptive DBS system with WebbiobankNewronika SpA received CE mark certification for its adaptive deep brain stimulation (aDBS) system, which integrates Webbiobank, its proprietary cloud-based neural data platform. The certification was granted on July 14, 2026, marking a regulatory milestone for the company's aDBS technology.